Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG79NT)

• Drug Name: LY-274614 Drug Info
• Synonyms: LY 235959; 137433-06-8; UNII-AR2BHC0C6P; LY-235959; AR2BHC0C6P; Decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid; 3-Isoquinolinecarboxylic acid, decahydro-6-(phosphonomethyl)-, (3S-(3alpha,4aalpha,6beta,8aalpha))-; LY-274614; C11H20NO5P; LY 274614; 136109-04-1; Tocris-1019; LY274614; LY235959; Biomol-NT_000192; SCHEMBL195083; BPBio1_001216; AC1L302W; CHEMBL1448057; CTK0H8339; MolPort-023-275-977; 3-Isoquinolinecarboxylicacid, decahydro-6-(phosphonomethyl)-, (3S,4aR,6S,8aR)-; ZINC31424744; AKOS024456335; NCGC00024942-02

Indication

Disease Entry	ICD 11	Status	REF
Dementia	6D80-6D86	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 131938
  CAS Number: CAS 137433-06-8
  TTD Drug ID: DMG79NT

Molecule-Related Drug Atlas

Drug(s) Targeting N-methyl-D-aspartate receptor (NMDAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-glutamic acid	DM4PUDW	Schizophrenia	6A20	Approved	[3]
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[4]
Benzphetamine	DMIJATC	Obesity	5B81	Approved	[5]
Ketamine	DMT5HA4	Anaesthesia	9A78.6	Approved	[6]
Felbamate	DM1V5ZS	Epilepsy	8A60-8A68	Approved	[7]
Memantine	DMD9WSC	Alzheimer disease	8A20	Approved	[8]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[9]
Levorphanol	DMGS80V	Pain	MG30-MG3Z	Approved	[10]
Magnesium Sulfate	DMVEK07	Acute pain	MG31	Approved	[11]
Magnesium	DMU4ORS	Ischemic stroke	8B11.5Z	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
N-methyl-D-aspartate receptor (NMDAR)	TT9IK2Z	NOUNIPROTAC	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001393)
• [2] The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 1994 Jan;56(1):69-75.
• [3] Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
• [4] How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
• [5] Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
• [6] Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
• [7] Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
• [8] The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
• [9] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [10] Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
• [11] Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
• [12] Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.